| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 123.44 | 10.9% | 46.3% |
| Total Income | 123.97 | 10.5% | 45.7% |
| Expenditure | 100.79 | 7.5% | 36.9% |
| PBT | 22.35 | 21.1% | 95.9% |
| Net Profit | 16.01 | 13.4% | 87.5% |
| OPM | 23.59% | 0.81pp | 18.84pp |
| NPM | 12.91% | 0.33pp | 2.87pp |
| EPS | 15.43 | 13.5% | 87.5% |
Kwality Pharmaceuticals Reports 46% YoY Revenue Surge in Q3 FY26, EBITDA Expands 67%
12 Feb 2026 · 12 Feb, 12:01 pm
Summary
Kwality Pharmaceuticals Ltd. delivered a robust and consistent performance during Q3 and the first nine months of FY26, underscoring the company’s disciplined execution, expanding international footprint, and unwavering focus on complex and differentiated products. The company achieved significant year-on-year growth in revenue, EBITDA, and Profit After Tax (PAT) during the period.
Key Highlights
- 1
Consolidated revenue surged 46% YoY in Q3FY26, climbing from ₹84 crore in Q3 FY25 to ₹123 crore.
- 2
EBITDA for the quarter expanded 67% YoY, from ₹18 crore in Q3 FY25 to ₹30 crore in Q3 FY26.
- 3
EBITDA margins enhanced from 22.0% to 24.3% in Q3 FY26.
- 4
Revenue advanced FY26, increasing from ₹255 crore to ₹346 crore for the first nine months.
- 5
Q3 FY26 PAT increased 78% YoY from ₹9 crore in Q3 FY25 to ₹16 crore, while 9M FY26 PAT grew 68% YoY from ₹25 crore to ₹42 crore.
- 6
KPL initiated multiple Bioequivalence (BE) and clinical studies in the injectables and oral solid dosage (OSD) segments.
- 7
Construction of the Hormone manufacturing facility manufacturing facility remains on schedule, with completion anticipated in H2 CY2026.
- 8
KPL achieved several new product registrations in the quarter, solidifying its foothold in regulated and semi-regulated markets.
- 9
Revenue for Q4 FY26 is projected at approximately ₹150 crore, with EBITDA expected to improve sequentially.
- 10
KPL targets a 30% CAGR, positioning it to achieve ₹1,000—1,100 crore in revenue by FY29.
Management Comments
Kwality Pharmaceuticals Ltd.
KPL delivered a robust and consistent performance during Q3 and the first nine months of FY26, underscoring the company’s disciplined execution, expanding international footprint, and unwavering focus on complex and differentiated products.
Informational and educational content only. Not investment advice.